Nephros: Record Quarter, But the Tariff Refund Masks the Real Story

A Record Quarter, With a Footnote

Nephros posted a record second quarter: revenue of $6.0M, up 36% year-over-year, net income of $1.2M versus $237K, and adjusted EBITDA of $1.3M. The CEO, Robert Banks, told investors the number was less important than where it came from — and he had a point. “More important than the headline number is the quality and breadth of the growth.” — Robert Banks, Chief Executive Officer · 2026-08-06 Programmatic product revenue grew by double digits; service-only revenue nearly tripled.

But the quarter also contained a $600K tariff refund. CFO Judy Krandel walked analysts through the mechanics: only $100K of that refund relates to inventory sold in the current period; the rest is a catch-up for goods sold in late 2025 and early 2026. The difference is material:

The $0.5 million of tariff refund corresponding to product sales made in prior periods increased our gross profit margin this past quarter by approximately 9 percentage points.

The reported 67% gross margin therefore flatters the underlying run rate, and management freely admitted tariff policy is still creating headwinds. “We expect that our gross profit margin will continue to be impaired as a result of U.S. tariff policy.” — Judy Krandel, Chief Financial Officer · 2026-08-06

The Real Story Is Recurring Revenue

A fuller reading of the quarter argues that Nephros is finally converting its platform into a recurring-revenue model. The key is Service revenue. Installation and scheduled replacement contracts are becoming a sticky stream, and the filter-tracker app automates reorders. Active customer sites rose only modestly, from 1,676 at the end of March to 1,724 today, but revenue per site is expanding. In May, Banks made the point directly: “Active customer sites is 1,676. It’s been growing very steadily, very healthy, not as fast as our revenue, which, in my mind, tells me that we’re earning more per customer.” — Robert Banks, Chief Executive Officer · 2026-05-08 That pattern is now even more pronounced in the June quarter.

This is not a brand-new strategy. On the third-quarter call last year, Banks highlighted the value of tracking filters: “Tracking app is doing well and continues to grow … creating more touch points.” — Robert Banks, CEO · 2025-11-07 The difference now is that those touch points are showing up in the revenue line. What was a product company with some service attachments is becoming a service-enabled product company with visible renewals.

New Products Remain on the Horizon

The same execution story runs through new products. PFAS, microplastics and nanoplastics are still in the education phase; management says they are “2, 3 quarters out” from meaningful contribution. Near-term growth remains broad based across the existing portfolio, with sterile processing perhaps the closest to commercialization. The company has also wrapped education into its offering via the Nephros Water Institute, which remains a demand-generation tool rather than a monetized service.

There is also a macro convergence at play here. Tariff refund appears in earnings calls across many industries, but for Nephros it is a one-time accounting credit, not a recurring revenue line. The real question is whether gross margin can hold above the high-50s once the refund is excluded, as the company invests in service headcount and absorbs a stronger euro and higher freight.

How the Market Is Voting

The stock already appears to be pricing in the inflection: over the last 90 days NEPH is up 37.8%, reaching a $4.76 peak on Aug 19 before the recent 14% drawdown. Yet the full tape is still down 97.5% from its 2010 high — this is a micro-cap comeback story, not a broad-market breakout. At the last 10-Q, valuation multiples had compressed dramatically: total revenue has climbed from roughly $2M in 2016 to $5M per the latest 10-Q, with management reporting $6M for the June quarter.

Risks are real: service revenue carries lower margins, tariffs continue under new legal authority, and the new-product pipeline is still unproven. But the numbers and the tone of the call suggest Nephros is executing on the recurring-revenue strategy it has been describing for over a year. “We recognize that a portion of this quarter’s reported profitability benefited from the onetime tariff refund. But the larger takeaway is the underlying growth of the business.” — Robert Banks, Chief Executive Officer · 2026-08-06 Those words are worth more than the accounting bounce — and they are exactly what the tape is beginning to reward.